A Phase III, Multi-Center, Placebo-Controlled Trial of Sorafenib (BAY 43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary)
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms MISSION
Sponsors Bayer; Bayer HealthCare

Most Recent Events

12 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
12 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database.
01 Dec 2015 Results published in the Journal of Thoracic Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight